{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T06:29:20Z","timestamp":1781332160622,"version":"3.54.1"},"reference-count":17,"publisher":"Elsevier BV","issue":"1-3","license":[{"start":{"date-parts":[[2009,3,1]],"date-time":"2009-03-01T00:00:00Z","timestamp":1235865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,3,1]],"date-time":"2009-03-01T00:00:00Z","timestamp":1235865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2009,3]]},"DOI":"10.1016\/j.schres.2008.11.017","type":"journal-article","created":{"date-parts":[[2008,12,24]],"date-time":"2008-12-24T08:42:43Z","timestamp":1230108163000},"page":"238-244","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Dose trends for second-generation antipsychotic treatment of schizophrenia and bipolar disorder"],"prefix":"10.1016","volume":"108","author":[{"given":"Leslie","family":"Citrome","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Reist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liisa","family":"Palmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie","family":"Montejano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greg","family":"Lenhart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Cuffel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Harnett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kafi N.","family":"Sanders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.schres.2008.11.017_bib1","series-title":"Time Series Analysis: Forecasting and Control","author":"Box","year":"1994"},{"issue":"1","key":"10.1016\/j.schres.2008.11.017_bib2","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2165\/00023210-200822010-00005","article-title":"Quetiapine: dose\u2013response relationship in schizophrenia","volume":"22","author":"Citrome","year":"2008","journal-title":"CNS Drugs"},{"issue":"5","key":"10.1016\/j.schres.2008.11.017_bib3","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1080\/10673220216279","article-title":"Optimal dosing of atypical antipsychotics in adults: a review of the current evidence","volume":"10","author":"Citrome","year":"2002","journal-title":"Harv. Rev. Psychiatry"},{"issue":"4","key":"10.1016\/j.schres.2008.11.017_bib4","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1097\/01.jcp.0000169623.30196.b9","article-title":"Dosing of second-generation antipsychotic medication in a state hospital system","volume":"25","author":"Citrome","year":"2005","journal-title":"J. Clin. Psychopharmacol."},{"issue":"12","key":"10.1016\/j.schres.2008.11.017_bib5","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.4088\/JCP.v66n1203","article-title":"Dosing of quetiapine in schizophrenia: how clinical practice differs from registration studies","volume":"66","author":"Citrome","year":"2005","journal-title":"J. Clin. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2008.11.017_bib6","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1176\/ps.2007.58.1.11","article-title":"Datapoints: the ups and downs of dosing second-generation antipsychotics","volume":"58","author":"Citrome","year":"2007","journal-title":"Psychiatr. Serv."},{"key":"10.1016\/j.schres.2008.11.017_bib7","unstructured":"Citrome, L., Jaffe, A., Levine, J., in press. How dosing of ziprasidone in a state hospital system differs from product labeling. J. Clin. Psychiatry."},{"issue":"2","key":"10.1016\/j.schres.2008.11.017_bib8","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1097\/01.jcp.0000117422.05703.ae","article-title":"Dose response and dose equivalence of antipsychotics","volume":"24","author":"Davis","year":"2004","journal-title":"J. Clin. Psychopharmacol."},{"issue":"4","key":"10.1016\/j.schres.2008.11.017_bib9","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/01.jcp.0000231536.79175.cd","article-title":"Hospitalization risks in the treatment of schizophrenia: comparison of antipsychotic medications","volume":"26","author":"Gianfrancesco","year":"2006","journal-title":"J. Clin. Psychopharmacol."},{"issue":"3","key":"10.1016\/j.schres.2008.11.017_bib10","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/j.1399-5618.2007.00394.x","article-title":"Hospitalization risks in the treatment of bipolar disorder: comparison of antipsychotic medications","volume":"9","author":"Gianfrancesco","year":"2007","journal-title":"Bipolar Disord."},{"issue":"2\u20133","key":"10.1016\/j.schres.2008.11.017_bib11","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.schres.2006.01.009","article-title":"Effect of initial ziprasidone dose on length of therapy in schizophrenia","volume":"83","author":"Joyce","year":"2006","journal-title":"Schizophr. Res."},{"issue":"11","key":"10.1016\/j.schres.2008.11.017_bib12","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/S0006-3223(01)01251-3","article-title":"Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient","volume":"50","author":"Kapur","year":"2001","journal-title":"Biol. Psychiatry"},{"issue":"5","key":"10.1016\/j.schres.2008.11.017_bib13","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1176\/appi.ajp.161.5.818","article-title":"A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone","volume":"161","author":"Mamo","year":"2004","journal-title":"Am. J. Psychiatry"},{"issue":"6","key":"10.1016\/j.schres.2008.11.017_bib14","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.pnpbp.2005.06.009","article-title":"Patterns of clinical use of antipsychotics in hospitalized psychiatric patients","volume":"29","author":"Mauri","year":"2005","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"issue":"2\u20133","key":"10.1016\/j.schres.2008.11.017_bib15","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.schres.2006.01.013","article-title":"Effect of initial ziprasidone dose on treatment persistence in schizophrenia","volume":"83","author":"Mullins","year":"2006","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2008.11.017_bib16","unstructured":"Pfizer, 2007. Geodon: US Package Insert for Geodon (ziprasidone HCl) and Geodon (ziprasidone mesylate) for Injection, LAB-0272-2.0. Available at: http:\/\/www.pfizer.com\/files\/products\/uspi_geodon.pdf. Accessed 2008 Aug 5."},{"issue":"11","key":"10.1016\/j.schres.2008.11.017_bib17","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1185\/030079907X233322","article-title":"Medication patterns and costs associated with olanzapine and other atypical antipsychotics in the treatment of bipolar disorder","volume":"23","author":"Zhu","year":"2007","journal-title":"Curr. Med. Res. Opin."}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996408005227?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996408005227?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:22:02Z","timestamp":1760296922000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996408005227"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,3]]},"references-count":17,"journal-issue":{"issue":"1-3","published-print":{"date-parts":[[2009,3]]}},"alternative-id":["S0920996408005227"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2008.11.017","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2009,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dose trends for second-generation antipsychotic treatment of schizophrenia and bipolar disorder","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2008.11.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}